Personal information

No personal information available

Activities

Collapse all

Employment (1)

Barts Health NHS Trust: London, GB

(Clinical Oncology)
Employment
Source: Self-asserted source
Melanie Powell

Works (21)

Endometrial cancer: the individual approach

The Lancet Oncology
2023-03 | Journal article
DOI: 10.1016/s1470-2045(23)00055-4
Part of ISSN: 1470-2045
Contributors: Melanie E Powell
Source: Self-asserted source
Melanie Powell

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

2022-09-14 | Preprint
DOI: 10.1101/2022.09.13.22279853
Contributors: Lisa Vermij; Jan J. Jobsen; Alicia León-Castillo; Mariel Brinkhuis; Suzan Roothaan; Melanie E. Powell; Stephanie M. de Boer; Pearly Khaw; Linda R. Mileshkin; Anthony Fyles et al.
Source: check_circle
Crossref

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

The Cochrane database of systematic reviews
2022-08 | Journal article
DOI: 10.1002/14651858.cd010260.pub3
PMID: 35994243
Contributors: Kokka F; Bryant A; Olaitan A; Brockbank E; Powell M; Oram D
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2022-06 | Journal article
DOI: 10.1038/s41379-022-01102-x
PMID: 35752743
PMC: PMC7613653
Contributors: Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Endometrial cancer

The Lancet
2022-04 | Journal article
DOI: 10.1016/s0140-6736(22)00323-3
Part of ISSN: 0140-6736
Contributors: Emma J Crosbie; Sarah J Kitson; Jessica N McAlpine; Asima Mukhopadhyay; Melanie E Powell; Naveena Singh
Source: Self-asserted source
Melanie Powell

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.

Nature communications
2022-03 | Journal article
DOI: 10.1038/s41467-022-29040-x
PMID: 35296668
PMC: PMC8927106
Contributors: Horeweg N; Workel HH; Loiero D; Church DN; Vermij L; Léon-Castillo A; Krog RT; de Boer SM; Nout RA; Powell ME et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

The role of radiotherapy in ovarian cancer

International Journal of Gynecological Cancer
2022-03 | Journal article
DOI: 10.1136/ijgc-2021-002462
Contributors: Kimberley Durno; Melanie E Powell
Source: check_circle
Crossref

Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial.

Clinical oncology (Royal College of Radiologists (Great Britain))
2021-12 | Journal article
DOI: 10.1016/j.clon.2021.11.015
PMID: 34903431
Contributors: Khaw P; Do V; Lim K; Cunninghame J; Dixon J; Vassie J; Bailey M; Johnson C; Kahl K; Gordon C et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy.

International journal of radiation oncology, biology, physics
2021-10 | Journal article
DOI: 10.1016/j.ijrobp.2021.09.042
PMID: 34610387
Contributors: Wortman BG; Post CCB; Powell ME; Khaw P; Fyles A; D'Amico R; Haie-Meder C; Jürgenliemk-Schulz IM; McCormack M; Do V et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.

Journal of the National Cancer Institute
2021-09 | Journal article
DOI: 10.1093/jnci/djab029
PMID: 33693762
PMC: PMC8418420
Contributors: Post CCB; Stelloo E; Smit VTHBM; Ruano D; Tops CM; Vermij L; Rutten TA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

PARP inhibitors and immunotherapy in ovarian and endometrial cancers.

The British journal of radiology
2021-06 | Journal article
DOI: 10.1259/bjr.20210002
PMID: 33882241
PMC: PMC8631040
Contributors: Miller RE; Lewis AJ; Powell ME
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.

Cancers
2020-12 | Journal article
DOI: 10.3390/cancers13010044
PMID: 33375706
PMC: PMC7795222
Contributors: Vermij L; Horeweg N; Leon-Castillo A; Rutten TA; Mileshkin LR; Mackay HJ; Leary A; Powell ME; Singh N; Crosbie EJ et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

International journal of radiation oncology, biology, physics
2020-10 | Journal article
DOI: 10.1016/j.ijrobp.2020.10.030
PMID: 33129910
Contributors: Post CCB; de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger NPB; Ledermann JA; Khaw P et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update.

International journal of radiation oncology, biology, physics
2020-09 | Journal article
DOI: 10.1016/j.ijrobp.2020.08.061
PMID: 32905846
PMC: PMC7856050
Contributors: Small W; Bosch WR; Harkenrider MM; Strauss JB; Abu-Rustum N; Albuquerque KV; Beriwal S; Creutzberg CL; Eifel PJ; Erickson BA et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-08 | Journal article
DOI: 10.1200/jco.20.00549
PMID: 32749941
PMC: PMC7527156
Contributors: León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

The Lancet Oncology
2019-09 | Journal article
DOI: 10.1016/s1470-2045(19)30395-x
Part of ISSN: 1470-2045
Contributors: Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Romerai D'Amico et al.
Source: Self-asserted source
Melanie Powell

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2018-06 | Journal article
DOI: 10.1038/s41379-018-0055-1
PMID: 29955143
Contributors: Auguste A; Genestie C; De Bruyn M; Adam J; Le Formal A; Drusch F; Pautier P; Crosbie EJ; MacKay H; Kitchener HC et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

The Lancet. Oncology
2018-02 | Journal article
DOI: 10.1016/s1470-2045(18)30079-2
PMID: 29449189
PMC: PMC5840256
Contributors: de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

Annals of oncology : official journal of the European Society for Medical Oncology
2018-02 | Journal article
DOI: 10.1093/annonc/mdx753
PMID: 29190319
PMC: PMC5834053
Contributors: de Boer SM; Wortman BG; Bosse T; Powell ME; Singh N; Hollema H; Wilson G; Chowdhury MN; Mileshkin L; Pyman J et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Gynecologic oncology
2017-05 | Journal article
DOI: 10.1016/j.ygyno.2017.05.014
PMID: 28511869
Contributors: Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P et al.
Source: Self-asserted source
Melanie Powell via Europe PubMed Central

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Oncology
2015-11 | Journal article
DOI: 10.1016/s1470-2045(15)00220-x
Part of ISSN: 1470-2045
Contributors: R Paul Symonds; Charlie Gourley; Susan Davidson; Karen Carty; Elaine McCartney; Debbie Rai; Susana Banerjee; David Jackson; Rosemary Lord; Mary McCormack et al.
Source: Self-asserted source
Melanie Powell

Peer review (3 reviews for 3 publications/grants)

Review activity for Gynecologic oncology. (1)
Review activity for International journal of radiation oncology, biology, physics. (1)
Review activity for Radiotherapy and oncology. (1)
How many people are using ORCID?